Prelude Therapeutics, Inc. (PRLD)
3.855
-0.04
(-0.90%)
USD |
NASDAQ |
Oct 12, 10:55
Prelude Therapeutics Enterprise Value : 176.15M for Oct. 9, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 09, 2026 | 176.15M |
| October 08, 2026 | 175.35M |
| October 07, 2026 | 171.36M |
| October 06, 2026 | 169.77M |
| October 05, 2026 | 166.58M |
| October 02, 2026 | 158.60M |
| October 01, 2026 | 168.17M |
| September 30, 2026 | 177.74M |
| September 29, 2026 | 181.73M |
| September 28, 2026 | 177.74M |
| September 25, 2026 | 174.95M |
| September 24, 2026 | 184.12M |
| September 23, 2026 | 209.65M |
| September 22, 2026 | 252.71M |
| September 21, 2026 | 240.75M |
| September 18, 2026 | 254.31M |
| September 17, 2026 | 230.38M |
| September 16, 2026 | 222.41M |
| September 15, 2026 | 226.40M |
| September 14, 2026 | 231.98M |
| September 11, 2026 | 231.98M |
| September 10, 2026 | 238.36M |
| September 09, 2026 | 271.86M |
| September 08, 2026 | 288.61M |
| September 04, 2026 | 301.37M |
| Date | Value |
|---|---|
| September 03, 2026 | 284.62M |
| September 02, 2026 | 298.97M |
| September 01, 2026 | 303.76M |
| August 31, 2026 | 312.53M |
| August 28, 2026 | 302.16M |
| August 27, 2026 | 371.55M |
| August 26, 2026 | 389.10M |
| August 25, 2026 | 391.49M |
| August 24, 2026 | 381.92M |
| August 21, 2026 | 394.68M |
| August 20, 2026 | 384.31M |
| August 19, 2026 | 326.89M |
| August 18, 2026 | 324.50M |
| August 17, 2026 | 314.93M |
| August 14, 2026 | 308.54M |
| August 13, 2026 | 293.39M |
| August 12, 2026 | 322.90M |
| August 11, 2026 | 290.20M |
| August 10, 2026 | 251.12M |
| August 07, 2026 | 256.70M |
| August 06, 2026 | 239.16M |
| August 05, 2026 | 227.99M |
| August 04, 2026 | 226.40M |
| August 03, 2026 | 216.03M |
| July 31, 2026 | 232.78M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Q32 Bio, Inc. | 96.99M |
| Intellia Therapeutics, Inc. | 1.466B |
| Twist Bioscience Corp. | 9.941B |
| Beam Therapeutics, Inc. | 1.748B |
| Revolution Medicines, Inc. | 37.91B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -13.92M |
| Revenue (Quarterly) | 5.704M |
| Total Expenses (Quarterly) | 19.62M |
| EPS Diluted (Quarterly) | -0.1415 |
| Gross Profit Margin (Quarterly) | 93.81% |
| Profit Margin (Quarterly) | -244.1% |
| Earnings Yield | -20.44% |
| Normalized Earnings Yield | -20.44 |